A large body of studies over the decades by both academic and pharmaceutical laboratories has firmly established a pivotal role for hyperactivation and genomic alterations in human epidermal growth factor receptors (HER1-4) in tumor progression; this consequently has made HERs the basis of most targeted therapeutics for the treatment of human cancer [6,7,8,9,10,11,12,13,14]. This evidence concerns the gene EGFR and cancer.